Open AccessBlock‑Removed Immunoglobulin Technology to enhance rituximab effector function by counteracting CA125‑mediated immunosuppression
Author(s) -
Luigi Grasso,
J. Bradford Kline,
Nicholas C. Nicolaides
Publication year - 2021
Publication title -
oncology letters
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2021.13120
Subject(s) - antibody dependent cell mediated cytotoxicity , rituximab , antibody , cd20 , complement dependent cytotoxicity , cytotoxicity , immunology , fragment crystallizable region , lymphoma , immunosuppression , cancer research , medicine , monoclonal antibody , biology , in vitro , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom